News Quantified

EDIT – editas medicine, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Editas Medicine to Participate in Upcoming Investor Conferences [Yahoo! Finance]

Editas Medicine to Participate in Upcoming Investor Conferences

Genflow Biosciences PLC Announces Directorate Change [Yahoo! Finance]

-3.1%

BEAT

34.5%

MISS

-2.6%

MISS

-7.8%

MISS

Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: Burkly Linda

Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: Parison Amy

Form 4 Editas Medicine, Inc. For: Dec 03 Filed by: O'Neill Gilmore Neil

Form 144 Editas Medicine, Inc. Filed by: O'Neill Gilmore Neil

Top News Gainers

6/7 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%

11/12 Q3/2019 9/30/2019 EPS -0.660 ZacksConsensus -0.730 ActVsEst 0.070 - Beat 6.9%

3/5 Editas Medicine Inc (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock. 5.2%

3/4 Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10 5.1%

8/29 Editas Medicine to Participate in Upcoming Investor Conferences 4.5%

6/14 Form 4 Editas Medicine, Inc. For: Jun 12 Filed by: Hirsch Andrew 4.0%

10/19 Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth [Yahoo! Finance News] 3.7%

11/13 Editas Expands Its Celgene Partnership After Another Strong Quarter [The Motley Fool] 3.7%

11/28 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 3.6%

5/4 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.4%

Top News Decliners

5/10 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.9%

4/1 Better Buy: Editas Medicine vs Sangamo Therapeutics [The Motley Fool] -8.1%

2/26 Form S-8 Editas Medicine, Inc. -6.8%

2/21 Editas Medicine Inc (NASDAQ: EDIT) is now covered by analysts at Wells Fargo & Co. They set an "equal weight" rating and a $28.00 price target on the stock. -6.7%

2/22 Better Buy: Editas Medicine vs. Intellia [The Motley Fool] -6.2%

7/30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update -5.8%

8/27 Editas Medicine Inc (NASDAQ: EDIT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -5.1%

4/30 Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update -4.9%

11/26 Better Buy: Editas Medicine or Sangamo Therapeutics? [The Motley Fool] -4.6%

3/20 Editas Medicine Inc (NASDAQ: EDIT) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day